新城疫病毒联合化疗对晚期非小细胞肺癌的疗效和安全性评价

  目的  探讨新城疫病毒在ⅢB、Ⅳ期非小细胞肺癌(NSCLC)化疗中的作用。  方法  2005年7月~2008年5月, 在辽宁省肿瘤医院收治的146例非小细胞肺癌患者, 随机分为实验组与对照组。实验组73例, 采用新城疫病毒联合长春瑞滨+卡铂方案化疗; 对照组73例, 单纯采用长春瑞滨+卡铂方案化疗。每28天为1个周期, 化疗4个周期。每2个周期评价疗效, 并监测治疗前后患者白细胞、血小板、T细胞亚群CD4/CD8变化。  结果  实验组和对照组的有效率分别为50.68%和41.10%(P < 0.05)。实验组不良反应较对照组轻, 差异有统计学意义(P < 0.05)。实验组治疗前后CD4/CD8分别为1.22+0.94和1.59±1.17, 差异有统计学意义(P < 0.05)。  结论  新城疫病毒联合长春瑞滨+卡铂方案治疗ⅢB、Ⅳ期非小细胞肺癌(NSCLC)疗效好, 不良反应轻, 具有提高机体的免疫功能和改善患者生活质量的作用。 

Effect and Safety of the Newcastle Disease Virus Combined with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer

  Objective  To assess the effect and safety of the Newcastle disease virus in chemotherapy for patients with stages ⅢB and Ⅳ non-small cell lung cancer (NSCLC).  Methods  A total of 146 patients with advanced NSCLC were enrolled in this study. The patients were evenly randomized to experimental and control groups. Newcastle disease virus combined with the NP regimen (vinorelbine and carboplatin, n=73) was given to the experimental group, and NP regimen only (n=73) was given to the control group. The chemotherapy was performed for four cycles every 28 days, and the therapeutic efficacy was evaluated every 2 weeks. The following indicators were observed: levels of hemoglobin, white blood cell, platelet, and T cell subpopulation in the blood, as well as short-term efficacy, adverse effects, and quality of life.  Results  The response rate in the experimental and control groups were 50.68% and 41.10%, respectively (P < 0.05). The Karnofsky performance score were higher in the experimental group than in the control group (P < 0.01). Gastrointestinal reactions, impairment of renal functions, nausea, and vomiting, diarrhea, and myelosuppression were alleviated in the experimental group compared with the control group; the difference was significant (P < 0.05). The CD4/CD8 ratio increased in the experimental group (P < 0.05) but decreased in the control group (P > 0.05).  Conclusion  The Newcastle disease virus combined with the NP regimen shows a better therapeutic effect, reduces the adverse effects of chemotherapy, and improves the quality of life of patients with stages Ⅲ and Ⅳ NSCLC.